CD8A and neoplasm: We then compared proteomes of CD8+ tumor-infiltrating lymphocytes (TILs) of which greater than 60% were PD-1+ (10 patients) to proteomes of CD8+ TILs of which less than 20% were PD-1+ (15 patients).